DCGI Approves Zytorvi for Advanced Esophageal Cancer Treatment in India

The Drug Controller General of India (DCGI) has approved Zytorvi (Toripalimab) for the treatment of advanced esophageal cancer. This advanced immunotherapy drug is now authorized for use in India.                 Zytorvi is a significant breakthrough in the fight against esophageal cancer, offering a new and potentially more effective treatment option for patients.                 The DCGI's approval follows extensive clinical trials that demonstrated the efficacy and safety of Zytorvi in treating advanced esophageal cancer.                 This development is expected to bring hope to patients and their families battling this challenging disease.